Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Cash: 2009-2025

Historic Change in Cash for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $71.1 million.

  • Myriad Genetics' Change in Cash rose 726.74% to $71.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year increase of 81.45%. This contributed to the annual value of -$29.0 million for FY2024, which is 138.93% down from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Change in Cash is $71.1 million, which was up 510.98% from -$17.3 million recorded in Q2 2025.
  • Myriad Genetics' Change in Cash's 5-year high stood at $176.8 million during Q3 2021, with a 5-year trough of -$93.2 million in Q1 2022.
  • For the 3-year period, Myriad Genetics' Change in Cash averaged around $8.0 million, with its median value being -$3.3 million (2023).
  • As far as peak fluctuations go, Myriad Genetics' Change in Cash crashed by 969.70% in 2024, and later spiked by 726.74% in 2025.
  • Over the past 5 years, Myriad Genetics' Change in Cash (Quarterly) stood at -$36.4 million in 2021, then dropped by 21.70% to -$44.3 million in 2022, then skyrocketed by 226.19% to $55.9 million in 2023, then plummeted by 96.24% to $2.1 million in 2024, then spiked by 726.74% to $71.1 million in 2025.
  • Its last three reported values are $71.1 million in Q3 2025, -$17.3 million for Q2 2025, and -$10.9 million during Q1 2025.